KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Investing Activities: 2009-2024

Historic Cash from Investing Activities for Emergent BioSolutions (EBS) over the last 16 years, with Dec 2024 value amounting to $125.2 million.

  • Emergent BioSolutions' Cash from Investing Activities fell 103.04% to -$3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.9 million, marking a year-over-year increase of 19.60%. This contributed to the annual value of $125.2 million for FY2024, which is 41.03% down from last year.
  • Latest data reveals that Emergent BioSolutions reported Cash from Investing Activities of $125.2 million as of FY2024, which was down 41.03% from $212.3 million recorded in FY2023.
  • Emergent BioSolutions' Cash from Investing Activities' 5-year high stood at $212.3 million during FY2023, with a 5-year trough of -$381.3 million in FY2022.
  • Its 3-year average for Cash from Investing Activities is -$14.6 million, with a median of $125.2 million in 2024.
  • As far as peak fluctuations go, Emergent BioSolutions' Cash from Investing Activities crashed by 70.15% in 2022, and later spiked by 155.68% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Cash from Investing Activities (Yearly) stood at -$151.9 million in 2020, then slumped by 47.53% to -$224.1 million in 2021, then crashed by 70.15% to -$381.3 million in 2022, then spiked by 155.68% to $212.3 million in 2023, then slumped by 41.03% to $125.2 million in 2024.